STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70346 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Carles Iniesta-Navalón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Adalimumab, Drug Monitoring, Infliximab, Antirheumatic Agents. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Objective
The purpose of this study is to identify risk factors associated with pharmacokinetic failure, defined as immunogenicity or subtherapeutic drug concentrations, in patients treated with infliximab (IFX) or adalimumab (ADA), and to develop a predictive model (STRATIfy‐PK SCORE) to support proactive therapeutic drug monitoring (TDM).
Methods
A retrospective cohort study was conducted in adult patients with immune‐mediated inflammatory diseases receiving IFX or ADA. Pharmacokinetic failure was defined by anti‐drug antibodies or subtherapeutic serum concentrations, based on indication‐specific therapeutic thresholds. Multivariate logistic regression models were developed separately for each drug and outcome. Model performance was assessed using area under the receiver operating characteristic curve (AUC) and calibration plots.
Results
Of 457 patients (298 ADA, 159 IFX), 1035 TDM samples were analysed. Subtherapeutic drug concentrations occurred in 59.7% of patients, and immunogenicity was observed in 18.8%. In IFX‐treated patients, predictors of immunogenicity included prior low induction or maintenance levels, ankylosing spondylitis and rheumatoid arthritis. For ADA, predictors were non‐adherence, prior low maintenance levels, early TDM, monotherapy and rheumatic diagnoses. Predictors of subtherapeutic concentrations included prior low maintenance levels, early TDM, high inflammatory burden, and rheumatoid arthritis for IFX, and prior low maintenance levels, ankylosing spondylitis and early TDM for ADA. Predictive models demonstrated good discriminative performance (AUC 0.795–0.800 for immunogenicity; 0.686–0.700 for subtherapeutic levels) and satisfactory calibration.
Conclusions
STRATIfy‐PK SCORE allows early identification of patients at high risk of pharmacokinetic failure and may support proactive, personalized TDM strategies to improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Reina Sofia Hospital of Murcia, Murcia, Spain.
- Pharmacokinetics and Applied Pharmacotherapy Group, Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Murcia, Spain.
- Department of Pharmacology School of Medicine, University of Murcia, Murcia, 30120, Spain.
- Department of Public Health, University of Murcia, Murcia, Spain.
- Department of Rheumatology, Reina Sofia Hospital of Murcia, Murcia, Spain.
- Department of Gastroenterology, Reina Sofia Hospital of Murcia, Murcia, Spain.
ORCID-Profile: Carles Iniesta-Navalón
Zitieren
APA
Iniesta-Navalón, C., Ríos-Saorín, M., Rentero-Redondo, L., Gascón-Cánovas, J. J., González-Molina, M. R., Prado, I. N., Gómez-Espín, R., & Urbieta-Sanz, E. (2025). STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70346
Vancouver
Iniesta-Navalón C, Ríos-Saorín M, Rentero-Redondo L, Gascón-Cánovas JJ, González-Molina MR, Prado IN, et al. STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70346
BibTeX
@article{IniestaNavaln2025,
author = {Iniesta-Navalón, Carles and Ríos-Saorín, Manuel and Rentero-Redondo, Lorena and Gascón-Cánovas, Juan José and González-Molina, Maria Rocio and Prado, Isabel Nicolás-De and Gómez-Espín, Rosa and Urbieta-Sanz, Elena},
title = {STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70346}
}
EUVIMED